Vivani Medical (NASDAQ: VANI) Continues to Progress Its Long-Acting NanoPortal Peptide-Implant Program With Two Assets in Active Development: LIBERATE-1 First-in-Human Phase 1 Clinical Study of NPM-115 (Exenatide Implant Using NanoPortal Technology) Completed With a Positive Safety and Tolerability Profile and Encouraging Performance Data; NPM-139 (Novel Semaglutide Implant) Has Demonstrated Greater Than 20% Sham-Adjusted Weight Loss for a Full Year From a Single Implant Administration in an Ongoing Preclinical Study, With Sustained Semaglutide Exposures Documented Over 231+ Days; Phase 1 Clinical Study Initiation for NPM-139 Is Targeted for H1 2026 Pending Regulatory Clearance, With Phase 2 Design Anticipated as a Randomized, Placebo-Controlled, Dose-Ranging Investigation Over 4 to 6 Months
Vivani Medical (NASDAQ: VANI) continues to progress its long-acting NanoPortal peptide-implant program with two assets in active development. NPM-115 (exenatide implant using NanoPortal technology): LIBERATE-1 first-in-human Phase 1 clinical study completed with a positive safety and tolerability profile plus encouraging performance data on exenatide release from the implant. NPM-139 (novel semaglutide implant): ongoing preclinical study has documented greater than 20% sham-adjusted weight loss for a full year from a single implant administration, with sustained semaglutide exposures documented over 231+ days. Recent preclinical readouts showed sustained semaglutide exposures and greater than 20% sham-adjusted weight loss with a single implant. Phase 1 clinical study initiation for NPM-139 is targeted for H1 2026 pending regulatory clearance. Phase 2 study design is anticipated as a randomized, placebo-controlled, dose-ranging investigation over 4 to 6 months to evaluate weight management in overweight or obese subjects. The long-acting implant delivery format addresses a substantial adherence-and-convenience gap in the current GLP-1 obesity drug class: weekly self-injection adherence in real-world claims data shows 30+ day dose gaps in a substantial share of patients within 12 months, and once-yearly implant dosing would materially change the adherence trajectory. Vivani's NanoPortal platform uses a micron-scale drug reservoir to release peptide payload at zero-order kinetics over extended durations. The category is early-stage but attracts increasing attention as GLP-1 franchise economics push toward longer-acting formats.